XGN

Exagen Inc. is a provider of autoimmune diagnostics focused on transforming care for patients with chronic and debilitating autoimmune conditions. The Company is focused on the design, development and commercialization of a portfolio of testing products under its AVISE brand, which allow for the differential diagnosis, prognosis and monitoring of complex rheumatic, autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Its testing products are supported by two proprietary technologies: its AVISE Lupus platform, which incorporates Cell-Bound Complement Activation Products (CB-CAPs) for diagnosing SLE, and a set of three biomarkers, the t-cell-based CB-CAP TC4d, along with two t-cell antibodies, TIgG, and TIgM (the T-Cell Biomarkers), all of which are incorporated into its AVISE CTD product. The Company’s flagship product, AVISE CTD, enables clinicians to more effectively diagnose complex autoimmune conditions.

Wall Street analysts forecast XGN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for XGN is 16.20 USD with a low forecast of 15.00 USD and a high forecast of 18.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Exagen Inc revenue for the last quarter amounts to 17.24M USD, increased 37.87 % YoY.

Exagen Inc. EPS for the last quarter amounts to -0.31 USD, increased 10.71 % YoY.

Exagen Inc (XGN) has 203 emplpoyees as of December 16 2025.

Today XGN has the market capitalization of 159.32M USD.